Skip to main content

Table1 Baseline clinical charateristics of the two groups and the comparisons of baseline blood lipid profiles and lipoprotein particles between them

From: Effect of PCSK9 inhibitor on lipoprotein particles in patients with acute coronary syndromes

Variable PCSK9i + statins (n = 54) Statins (n = 45)
Age (years), mean ± SD 60.6 ± 10.1 58.6 ± 10.6
Men, n (%) 34(63.0%) 30(66.7%)
Hypertension, n (%) 32(59.3%) 26(57.8%)
Diabetes, n (%) 15(27.8%) 10(22.2%)
Stroke history, n (%) 6(11.1%) 5(11.1%)
Dislipidemia, n (%) 25(46.3%) 20(44.4%)
MI history, n (%) 11(20.1%) 10(22.2%)
Prior PCI or CABG, n (%) 20(37.0%) 18(40.0%)
Family history of CAD, n (%) 17(31.5%) 13(28.9%)
Smoking, n (%) 22(41.1%) 23(51.1%)
Drinking, n (%) 20(37.0%) 16(35.6%)
BMI (kg/m2), mean ± SD 26 ± 5.0 27 ± 5.4
High waist circumference (women > 88 cm, men > 102 cm), n(%) 14(25.9%) 13(28.9%)
Statin use, n (%) 21(38.9%) 17(37.7%)
ACS type, n (%)
 STEMI 10(18.5%) 12(26.7%)
 NSTEMI 24(44.4%) 20(44.4%)
 UAP 20(37.0%) 13(28.9%)
Total cholesterol (mg/dl), mean ± SD 214.2 ± 42.4 189.7 ± 36.5
LDL-C (mg/dl), mean ± SD 123.7 ± 32.3 103.7 ± 28.1
IDL-C (mg/dl), mean ± SD 15.5 ± 9.1 13.6 ± 7.6
VLDL-C (mg/dl), mean ± SD 31.9 ± 17.9 25.3 ± 15.5
HDL-C (mg/dl), mean ± SD 43.9 ± 7.8 44.3 ± 9.4
Lp(a) (nmol/l), median (Q1, Q3) 73.1(13.7,102.3) 32.7(8.2,49.1)
ApoB (mg/dl), mean ± SD 108.7 ± 24.2 93.0 ± 20.8
LDL-P total (nmol/l), mean ± SD 1573.9 ± 375.3 1317.8 ± 337.8
VLDL-P (nmol/l), mean ± SD 237.5 ± 106.0 182.8 ± 89.2
IDL-P (nmol/l), mean ± SD 91.0 ± 47.7 88.6 ± 43.3
  1. PCI percutaneous coronary intervention, CABG coronary artery bypass graft, BMI body mass index, STEMI stsegment elevation myocardial infarction, NSTEMI non-ST-segment elevation myocardial infarction, UAP unstable angina pectoris, LDL-C low-density lipoprotein cholesterol, IDL-C intermediate-density lipoprotein, VLDL-C very low-density lipoprotein cholesterol, HDL-C high-density lipoprotein cholesterol, Lp(a) Lipoprotein a, ApoB Apolipoprotein B, LDL-P low-density lipoprotein particle concentration, VLDL-P very low-density lipoprotein particle concentration, IDL-P intermediate-density lipoprotein particle concentration, Q1, Q3 fifirst and third quartiles, SD standard deviation